Search this site

Olfactory Groove Meningioma - Presentation, Management, & Surgical Approaches An olfactory groove meningioma is a skull-base meningioma arising from the cribriform plate and frontoethmoidal dura of the anterior cranial fossa. It grows between the frontal lobes, causes progressive frontal lobe compression, and often presents with anosmia, personality changes, cognitive decline, visual impairment, and massive bifrontal edema. These tumors frequently cause hyperostosis of the cribriform plate and can extend inferiorly into the ethmoid sinuses or superiorly into the interhemispheric fissure. Their slow growth leads to late diagnosis, often when large. Q. What are the key anatomical structures relevant to olfactory groove meningiomas? Anterior Cranial Fossa Anatomy Floor formed by frontal bone, cribriform plate, and planum sphenoidale. The cribriform plate houses olfactory fila and forms the site of dural attachment for most OGMs. The crista galli is a midline projection to which falx attaches; hyperostosis here is common. The ethmoid labyrinth and sinuses lie just below, important for risk of CSF leak. Vascular Relationships The anterior cerebral arteries (ACAs) run along the interhemispheric fissure. Tumor typically displaces ACAs laterally. The A2 segments and pericallosal arteries can be splayed across the superior pole. Recurrent artery of Heubner may be at risk during devascularization. Frontal Lobe Considerations OGMs compress the basal medial frontal lobes causing behavioral/personality changes. They often induce extensive vasogenic edema, due to venous compression and pial invasion. Olfactory Apparatus Olfactory nerves run from nasal mucosa through the cribriform foramina to olfactory bulbs. Small tumors may allow unilateral preservation via pterional or unilateral subfrontal route. Large tumors typically destroy both bulbs, producing irreversible anosmia. Venous Drainage The anterior superior sagittal sinus and frontal bridging veins drain the medial frontal lobes. Retraction injury or venous sacrifice increases risk of edema or venous infarct. Optic Apparatus Large OGMs may compress optic nerves/chiasm anteriorly or inferiorly. Can cause visual decline via mass effect or vasogenic edema. Q. Is embryology relevant in the development of olfactory groove meningiomas? Only indirectly. OGMs arise from meningothelial cells associated with neural crest; derived dura of the anterior cranial base and mesodermal components of the cribriform plate. Embryologically, the anterior skull base forms from a combination of prechordal mesoderm and neural crest cells, which explains the tendency of meningiomas in this region to produce hyperostosis and invade bone. Q. How common are olfactory groove meningiomas? OGMs account for 8–13% of all intracranial meningiomas (Al-Mefty). More common in middle-aged to elderly women, consistent with general meningioma epidemiology. Present later than other skull base tumors because symptoms are subtle and slowly progressive. Can reach giant sizes (>4–6 cm) before diagnosis. Q. What are the key pathological features of olfactory groove meningiomas? Most OGMs are WHO Grade 1, meningothelial or transitional types. Tend to produce hyperostosis of underlying bone due to tumor infiltration or reactive osteoblastic activity. Microscopic invasion of dura and bone is common. Pial invasion is associated with increased edema. Q. What is the WHO 2021 integrated classification’s relevance to OGMs? Most OGMs remain Grade 1, unless atypical features present: High mitotic index Brain invasion Necrosis Sheeting architecture Molecular markers: NF2 mutations are less common than convexity tumors. TERT promoter mutation or CDKN2A/B deletion upgrades tumor to Grade 3. SMO and AKT1 mutations seen in anterior skull base meningiomas. Q. What is the typical origin and growth pattern of OGMs? Originate from cribriform plate, frontoethmoidal region, falcine dura anteriorly. Grow symmetrically upward, expanding between the frontal lobes (“butterfly pattern”). May extend downward into the ethmoid sinuses or nasal cavity. Frequently extend posteriorly into interhemispheric fissure. Q. What are the classic presenting symptoms? Olfactory Impairment Anosmia or hyposmia is the earliest symptom. Often unnoticed by the patient. Behavioral and Cognitive Changes: Frontal lobe compression causes: Apathy Disinhibition Personality change Impaired judgment Memory decline Often misdiagnosed as psychiatric or degenerative conditions. Visual Symptoms: Due to compression of optic nerves/chiasm. May present with blurred vision, decreased acuity, field defects. Headache: Common, due to mass effect or edema. Seizures: Less common than in convexity tumors, but possible if extension to frontal cortex present. Large Tumor Presentation: Gait disturbance Incontinence (frontal lobe syndrome) Features of increased intracranial pressure Q. Why do OGMs cause such marked frontal lobe edema? Mechanisms include: Venous outflow obstruction from compression of frontal bridging veins. Pial invasion altering blood–brain barrier. Mass effect on medial frontal lobes. Hyperostotic bone pressing on dura and venous channels. Extensive edema correlates with postoperative recovery challenges. Q. What findings on examination may suggest an OGM? Complete anosmia. Frontal release signs (grasp, snout reflex). Apathy, impaired executive function. Optic disc pallor if chronic compression is present. Rarely, proptosis from anterior extension. Q. What are the classic radiologic features of an olfactory groove meningioma on CT and MRI? CT typically shows a midline anterior skull-base mass arising from the cribriform plate with hyperostosis of the olfactory groove or crista galli. Bone infiltration is common and may extend into ethmoid sinuses. Calcification may be present. MRI demonstrates an extra-axial lesion with a broad dural attachment, isointense signal on T1 and T2, and homogeneous contrast enhancement. A dural tail may be present. Prominent bifrontal vasogenic edema out of proportion to tumor size is characteristic. Tumor may elevate and laterally displace the anterior cerebral arteries, and may compress the optic apparatus posteriorly. Q. What MRI findings help distinguish OGMs from other anterior skull-base meningiomas? OGMs typically arise from the midline cribriform plate and therefore show symmetrical bifrontal displacement, lateral splaying of the ACAs, and early involvement of olfactory bulbs. Tuberculum sellae meningiomas elevate the chiasm and displace ACAs superiorly rather than laterally. Planum sphenoidale meningiomas extend posteriorly toward the chiasm earlier than OGMs. Prominent frontal lobe edema is more pronounced in OGMs due to venous congestion and pial invasion. Q. How does an OGM appear on angiography when performed? Angiography shows a mass with primary feeders from the anterior and posterior ethmoidal arteries (branches of the ophthalmic artery). There may be tumor blush or early venous filling. ACAs are displaced laterally. Preoperative embolization is rarely helpful because of ophthalmic artery risk. Q. What imaging signs help predict the risk of postoperative edema or venous infarction? Severe preoperative bifrontal edema, compression or distortion of frontal draining veins, invasion of pial surfaces, and hyperostosis causing venous obstruction all increase postoperative edema risk. Large tumors with tight interhemispheric corridors also predispose to venous congestion after devascularization. Q. What is the differential diagnosis of an anterior cranial fossa mass in this region? Differential diagnoses include planum sphenoidale meningioma, tuberculum sellae meningioma, esthesioneuroblastoma (especially when there is intranasal extension with cystic superior poles), sinonasal carcinoma with intracranial extension, metastatic lesions, and large olfactory neuroepitheliomas. Arachnoid cysts and dermoids are rare differentials but may appear anteriorly. Q. How do you differentiate OGM from esthesioneuroblastoma on imaging? Esthesioneuroblastoma often shows a dumbbell-shaped mass through the cribriform plate with enhancement in both nasal cavity and anterior cranial fossa and may have peripheral cysts at the intracranial margin. OGMs are entirely dural-based with hyperostosis and lack the multilobulated appearance. Esthesioneuroblastoma may enhance heterogeneously and invade the nasal cavity more aggressively. Q. What are the principles of management for olfactory groove meningiomas? Management depends on tumor size, symptoms, and radiologic progression. Small, asymptomatic tumors may be observed. Symptomatic tumors, especially those causing personality change, visual decline, or significant edema, require surgical resection. Surgery aims for gross total removal including involved dura and hyperostotic bone. Approach selection depends on tumor size, height, lateral extension, olfactory preservation goals, and surgeon experience. Q. When is observation appropriate in a patient with OGM? Observation is appropriate for elderly or frail patients with small, minimally symptomatic lesions, especially if anosmia already exists and the tumor is slow-growing. Regular MRI surveillance every 6 to 12 months is required. Significant growth or new cognitive deficits prompt reconsideration for surgery. Q. When is surgery clearly indicated? Surgery is indicated for symptomatic tumors causing personality change, seizures, visual deficits, significant edema, or mass effect. Surgery is also indicated for tumors extending inferiorly through the cribriform plate with risk of CSF leak or infection, or for patients with progressive radiologic enlargement. Q. What are the main surgical options for OGM and what factors influence the choice of approach? Major approaches include bifrontal subfrontal (bicoronal), unilateral subfrontal or pterional/orbitofrontal, and extended endoscopic endonasal (EEA). Choice depends on tumor size, height above planum, lateral extension, vascular encasement, olfactory preservation goals, bone involvement, sinus extension, and surgeon expertise. Bifrontal approach is preferred for large midline tumors, tumors with significant lateral extension, and tumors with hyperostosis requiring bone removal. Pterional/orbitofrontal approach is useful for unilateral or moderately sized tumors where unilateral olfaction may be preserved. EEA is used for midline tumors with predominant inferior extension, minimal lateral spread, and when early devascularization and avoidance of brain retraction are priorities. Q. What are the advantages of the bifrontal (bicoronal) subfrontal approach? This approach provides excellent midline exposure, allows early access to tumor base and devascularization, facilitates bilateral frontal lobe decompression, allows removal of hyperostotic bone, and supports complete reconstruction of the anterior skull base. It is ideal for giant tumors. Both ACAs and their branches are well visualized from above. Q. What are the disadvantages of the bifrontal approach? It requires significant frontal lobe retraction, increases risk of venous injury to frontal bridging veins, may worsen postoperative edema, and commonly violates the frontal sinus, increasing risk of CSF leak. It sacrifices remaining olfaction if present. The large exposure increases operative time and potential blood loss. Q. What are the advantages of the unilateral subfrontal or pterional/orbitofrontal approach? This approach reduces brain retraction, especially when combined with extradural anterior clinoidectomy or orbitotomy. It allows potential unilateral olfactory preservation, provides early access to ipsilateral feeding vessels, and avoids frontal sinus entry if the incision is placed carefully. It is excellent for small to medium tumors with asymmetric extension. Q. What are the disadvantages of the pterional/orbitofrontal approach? Exposure of the contralateral side is limited. Superior extension beyond the falx may be difficult to reach. Large midline tumors may result in blind spots. Hyperostotic bone cannot be widely removed without converting to a larger exposure. Contralateral ACA branches may not be fully visualized. Q. What are the advantages of the extended endoscopic endonasal approach (EEA)? EEA provides a direct midline, brain-retraction-free route with early devascularization at the skull-base dura. It avoids manipulation of frontal lobes and venous structures, reducing edema. It allows aggressive removal of hyperostotic bone and reconstruction from below. It is ideal for tumors with inferior extension through ethmoid sinuses. Q. What are the disadvantages or limitations of EEA? It carries a higher risk of postoperative CSF leak, requires extensive reconstruction of the skull base, and may not permit complete resection of lateral tumor components beyond the medial orbit or optic nerves. Vascular control may be more limited than with transcranial routes. Very large or superiorly projecting tumors may not be fully accessible. Q. When do you choose bifrontal over pterional or EEA? A bifrontal approach is chosen for giant midline tumors, tumors with significant lateral expansion, those with superior extension into interhemispheric fissure, when wide removal of hyperostotic bone is needed, or when bilateral ACA visualization is necessary. It is also chosen when the tumor rises significantly above the planum and is not accessible from below. Q. When is EEA superior to open approaches? EEA is superior when the tumor is midline, relatively flat against the skull base, has significant inferior extension, and does not extend far laterally beyond the medial orbital walls. It is also advantageous when avoidance of frontal lobe retraction is a priority, particularly in patients with severe preoperative edema. Q. How do you manage hyperostosis in OGMs? Removal of hyperostotic bone is essential to reduce recurrence risk. In bifrontal approaches, the hyperostotic crista galli and involved cribriform plate are drilled away. Reconstruction is required to prevent CSF leak. In EEA, hyperostotic bone is drilled directly from below while preserving vascularized mucosa for reconstruction. Q. How do you manage the frontal sinus if violated during a bifrontal approach? The sinus is exenterated, mucosa fully removed, and nasofrontal ducts obliterated. Fat graft packing or pericranial flap is used to isolate the sinus from the intracranial space. Proper sealing reduces risk of postoperative CSF leak or mucocele formation. Q. How will you perform a bifrontal (bicoronal) subfrontal approach for an olfactory groove meningioma? I will position the patient supine with the head elevated, slightly extended, and secured in a three-pin fixation device. I will avoid excessive extension to protect venous drainage. I will mark and infiltrate a bicoronal incision behind the hairline, elevate the scalp flap anteriorly, and preserve a generous vascularized pericranial flap for skull-base reconstruction. I will expose the frontal bone down to the orbital rims. I will perform a bifrontal craniotomy extending from one temporal line to the other, staying above the frontal sinus if possible. If the frontal sinus is entered, I will exenterate the mucosa, pack the cavity with fat, and prepare it for obliteration later. I will remove the anterior skull base bone overlying the crista galli and drill hyperostotic bone to expose the tumor attachment. I will open the dura in a curvilinear fashion and protect the frontal veins. I will gently elevate the frontal lobes with minimal retraction, using gravity and CSF drainage from the lumbar drain if needed. I will identify the tumor capsule and begin internal decompression using bipolar cautery and suction. Once the tumor softens, I will progressively debulk it toward the base, preserving arachnoid planes around the ACAs and their branches. I will devascularize the tumor early by coagulating its dural base along the cribriform plate and frontoethmoidal dura. I will dissect the tumor from the medial frontal lobes, preserving pial surfaces. I will carefully follow the capsule toward the interhemispheric fissure and across the midline to free both sides symmetrically. When I reach the inferior extension, I will separate the tumor from the nasal mucosa while maintaining watertight dural margins. I will drill all hyperostotic bone and remove the crista galli completely. I will remove any tumor extension into the ethmoid sinuses if accessible from above. After confirming complete resection, I will reconstruct the anterior skull base using the pericranial flap, securing it over the defect to prevent CSF leak. I will close the dura primarily or with a graft, replace the bone flap, secure it with titanium plates, and close the scalp in layers. Q. What are the key advantages of the bifrontal approach during surgery? The bifrontal approach gives me wide midline exposure, allows symmetrical access to both frontal lobes, permits removal of hyperostotic bone, gives direct access to the tumor base for early devascularization, and allows full visualization of both A2 segments. It is ideal for giant tumors or those with significant bone invasion. Q. What are the main risks during the bifrontal approach? I must protect the frontal bridging veins, avoid aggressive frontal lobe retraction, prevent venous infarction, handle the frontal sinus meticulously, and manage large dead space after removal. I must be careful around A2 branches, especially Heubner. Postoperative edema is a significant concern due to manipulation of swollen frontal lobes. Q. How will you perform a pterional/orbitofrontal approach for olfactory groove meningioma? I will position the patient supine with the head rotated 30 degrees away from the side of approach and slightly extended. I will perform a standard frontotemporal (pterional) incision, elevate the scalp, and dissect the temporalis muscle inferiorly. I will fashion a pterional craniotomy and flatten the sphenoid wing with drilling. If needed, I will remove part of the orbital roof or perform a small orbitotomy to increase anterior exposure. I will open the dura in a curvilinear fashion and use CSF drainage from the sylvian fissure to relax the brain. I will gently retract the frontal lobe posteriorly and medially to expose the olfactory groove region from one side. I will identify the ipsilateral olfactory tract and bulb, preserving them when possible. I will expose the tumor capsule from the anteromedial direction. I will begin by devascularizing the tumor base as much as possible from the ipsilateral side. I will internally debulk the tumor to collapse the capsule and gradually mobilize it from the medial frontal lobe, falx, and ACAs. I will follow the tumor across to the contralateral side by working under the falx, limiting excessive traction. As I progress, I will detach the tumor from the cribriform plate region and carefully separate it from the nasal mucosa. I will drill any accessible hyperostotic bone. I will remove the tumor completely as long as the contralateral capsule is reachable without excessive traction. I will achieve meticulous hemostasis and close the dura Watertight. I will replace the bone flap, secure the orbitotomy if performed, and close the wound in layers. Q. How will you perform an endoscopic endonasal approach (EEA) for an olfactory groove meningioma? I will position the patient supine with the head slightly elevated and in slight extension. I will work with a binarial endoscopic four-hand technique. I will laterally outfracture the middle turbinates and perform a wide sphenoethmoidectomy to expose the skull base from lamina papyracea to lamina papyracea. I will identify the cribriform plate, planum sphenoidale, and fovea ethmoidalis. I will elevate mucosa and drill the bone of the cribriform plate, removing hyperostotic bone until dura is exposed widely. I will create a large dural opening over the tumor base, allowing early devascularization of the feeding vessels from the anterior and posterior ethmoidal arteries. I will debulk the tumor centrally using suction and ultrasonic aspirator, then work circumferentially to detach it from the frontal lobes while maintaining the arachnoid plane. I will follow the tumor superiorly until the capsule releases into the anterior cranial fossa. I will protect the ACAs and their branches by maintaining traction-free dissection from below. I will address lateral extensions as far as anatomically safe without compromising optic nerves or medial orbits. I will remove hyperostotic bone completely and clear any tumor invading the ethmoid sinuses. I will reconstruct the skull base using a multilayer technique with fascia, fat graft, and a vascularized nasoseptal flap to ensure a watertight seal. I will use lumbar drainage selectively. Q. What are the intraoperative limitations of EEA? Lateral and superior extensions may be inaccessible, vascular control is limited compared to craniotomy, reconstruction requires expertise, and CSF leak risk is higher. Tumors encasing ACAs are not ideal for this approach. Q. What are the important intraoperative principles across all approaches? I will debulk first, detach later. I will protect frontal veins to reduce edema. I will minimize frontal lobe retraction and use CSF drainage for relaxation. I will maintain arachnoid planes around ACAs and Heubner. I will devascularize early by addressing the dural base. I will remove the hyperostotic bone to reduce recurrence. I will ensure a watertight skull-base reconstruction. Q. What is the role of adjuvant radiotherapy in olfactory groove meningiomas? Adjuvant radiotherapy is recommended when subtotal resection is performed, when the tumor shows atypical or malignant features, or when molecular findings such as TERT mutation or CDKN2A/B deletion upgrade the tumor’s biological risk. Fractionated radiotherapy or stereotactic radiosurgery can control residual disease effectively, especially along the skull base or in locations where resection is unsafe. For WHO Grade 1 tumors with gross total resection, radiotherapy is not routinely required. Q. When is stereotactic radiosurgery preferred for OGMs? Stereotactic radiosurgery is preferred when the residual tumor is small, well circumscribed, not compressing the optic apparatus closer than tolerance limits, and situated along the skull base or in lateral extensions not amenable to EEA or reoperation. It is particularly useful for recurrent smaller lesions and in medically fragile patients. Q. What factors increase the likelihood of recurrence? Residual hyperostotic bone, incomplete dural removal, aggressive histologic features, pial invasion, atypical or malignant pathology, and molecular alterations such as TERT mutation or CDKN2A/B deletion increase recurrence risk. Tumors invading the sinuses or extending beyond safe surgical corridors also exhibit higher recurrence rates. Q. How do you manage recurrence after initial subtotal resection? Management includes radiologic surveillance for early detection of growth. If the recurrent tumor is small and accessible, reoperation may be performed with careful attention to prior scar tissue and vascular displacement. Radiosurgery or fractionated radiotherapy is often preferred to avoid additional morbidity. Molecular profiling may guide prognosis and follow-up intensity. Q. What are the common postoperative complications after resection of olfactory groove meningiomas? Complications include CSF leak, frontal lobe edema, venous infarction, anosmia, meningitis, seizures, hemorrhage, visual deterioration, and frontal syndrome with behavioral changes. Craniotomy-related complications include infection, wound healing issues, and sinus-related problems such as mucocele formation. EEA-specific complications include CSF leak and sinonasal morbidity. Q. Why is postoperative edema frequently seen after OGM surgery? The frontal lobes are often edematous preoperatively due to venous congestion and pial invasion. Surgical manipulation, retraction, or venous injury worsens edema. Postoperative venous outflow obstruction and the collapse of frontal lobes after tumor removal also contribute. Adequate venous preservation and slow decompression help mitigate edema. Q. How do you prevent CSF leak during anterior skull-base surgery? I will perform meticulous dural closure, remove all hyperostotic bone to achieve clean margins, and use a vascularized pericranial flap for reconstruction in bifrontal approaches. In EEA, I will use multilayer reconstruction with fascia, fat, and a vascularized nasoseptal flap, supported by tissue sealants and temporary lumbar drainage when necessary. Q. How do you manage postoperative CSF leak? Initial measures include lumbar drainage and head elevation. Persistent leaks require re-exploration of the repair or reinforcement with additional grafts. In EEA leaks, endoscopic revision with flap reinforcement is preferred. Antibiotic coverage and monitoring for meningitis are essential. Q. What are the visual complications after OGM surgery and why do they occur? Visual complications may include decreased acuity or field deficits due to optic nerve manipulation, vascular compromise, or edema postoperatively. Excessive traction on the frontal lobes or inadequate decompression of the optic apparatus may worsen vision. Rarely, postoperative hemorrhage can affect the chiasm or optic nerves. Q. What neurocognitive changes may occur after surgery? Temporary cognitive slowing, apathy, or impaired executive function may persist due to preoperative compression or postoperative edema. Gradual improvement occurs in most patients. Permanent deficits are associated with large tumors, prolonged compression, or venous infarction. Q. What is the prognosis after resection of olfactory groove meningiomas? Prognosis is excellent for WHO Grade 1 tumors when gross total resection is achieved. Long-term control rates exceed 85 to 90 percent. Cognitive recovery depends on preoperative severity and venous preservation. WHO Grade 2 or 3 tumors have higher recurrence rates and require closer surveillance and adjuvant therapy. Q. What factors predict favorable surgical outcomes? Smaller tumor size, minimal edema, preserved venous structures, complete dural and bone removal, and WHO Grade 1 histology predict good outcomes. Early diagnosis before significant frontal-lobe compression also improves cognitive recovery. Skilled skull-base reconstruction reduces complications. Q. How do you structure follow-up after OGM surgery? I will obtain an immediate postoperative MRI within 48 to 72 hours to assess resection extent. For WHO Grade 1 tumors with gross total resection, yearly MRI for 5 years is appropriate. If residual tumor is present or histology shows atypia, imaging every 6 months for the first 2 years is recommended, followed by annual scans. WHO Grade 3 tumors require imaging every 3 to 4 months initially. Q. What special considerations are needed in elderly patients? Elderly patients may present with significant frontal-lobe dysfunction that mimics dementia. Edema tolerance is lower, and venous injury is more dangerous. Minimally invasive approaches or observation may be appropriate for small tumors. Reconstruction strategies must account for frailty and wound healing. Q. What clinical pearls help reduce morbidity in OGM surgery? I will prioritize venous preservation, minimize frontal retraction, perform early devascularization, and avoid rapid decompression of tense frontal lobes. I will remove the hyperostotic bone thoroughly to prevent recurrence. I will handle the frontal sinus meticulously and construct a robust skull-base repair. I will anticipate edema and tailor postoperative care accordingly. Recalls: OGMs classically present with anosmia, personality change, and large bifrontal edema. CT shows hyperostosis; MRI shows a midline extra-axial mass displacing ACAs laterally. Bifrontal approach is ideal for giant midline tumors requiring extensive bone removal. Pterional approach may preserve unilateral olfaction and avoid frontal sinus violation. EEA avoids brain retraction and offers early devascularization for midline tumors. Hyperostotic bone removal is essential to reduce recurrence. CSF leak prevention relies on meticulous multilayer skull-base reconstruction. Cognitive recovery depends heavily on edema control and venous protection. WHO 2021 markers like TERT mutation determine prognosis and adjuvant needs. Long-term MRI surveillance is key, especially after STR or atypical histology.

CONGENITAL Aqueductal Stenosis → Klippel Feil Syndrome → Arachnoid Cyst → Lipomyelomeningocele → Basilar Invagination → Occult Spinal Dysraphisms & Filar Pathologies → Chiari Malformations → Myelomeningocele → Craniosynostosis → Myeloschisis → CVJ Anomalies → Os Odontoideum → Dandy Walker Malformation → Spinal Dysraphism → Encephalocele → Split Cord Malformation → Growing Skull Fracture → Tethered Cord Syndrome → Hydrocephalus → Torticollis →

Hemangioblastoma Hemangioblastoma is a benign, highly vascular tumor of vascular origin arising from the capillary network of the pia–arachnoid. Biologically and operatively, it behaves like a compact arteriovenous shunt lesion with a dominant inflow and a dominant outflow channel, rather than an infiltrative glioma, so safe surgery depends on stepwise devascularization and delayed venous control. Q. What is the genetics, epidemiology, diagnostic criteria, and phenotype of von Hippel–Lindau (VHL) disease associated with hemangioblastoma? Epidemiology: Occurs predominantly in adults aged 30–50 years with a slight male predilection. Approximately 75–80% are sporadic, while 20–25% are associated with VHL disease. Genetics & Pathophysiology: Caused by germline mutations in the VHL tumor suppressor gene on chromosome 3p25–26. Loss of VHL protein impairs degradation of hypoxia-inducible factor (HIF), causing hyper-expression of angiogenic mediators including VEGF and PDGF. Diagnostic Criteria: With family history: A single CNS hemangioblastoma or characteristic visceral lesion. Without family history: Multiple CNS hemangioblastomas, or one CNS hemangioblastoma PLUS a characteristic visceral manifestation. Genetic confirmation establishes diagnosis and enables family screening. Associated VHL Manifestations: Retinal hemangioblastomas, renal cell carcinoma (RCC), pheochromocytoma, pancreatic cysts and neuroendocrine tumors, endolymphatic sac tumors, and epididymal/broad ligament cystadenomas. Clinical Significance: In VHL, treatment shifts from curing a single lesion to managing a lifelong tumor-predisposition state through selective, surveillance-driven interventions. Q. Describe the histopathology and common sites of involvement of hemangioblastoma. Histopathology: WHO Grade 1 tumor composed of lipid-rich stromal cells embedded within a dense capillary network. Stromal cells represent the neoplastic driver and express markers such as inhibin A and VEGF. Lesions are morphologically classified as cystic with a mural nodule or solid. Intracranial Sites: Primarily posterior fossa (cerebellar hemispheres, vermis, brainstem/medulla). Supratentorial occurrences are rare. Spinal Cord Sites: Intramedullary parenchyma or cord surface (predominantly dorsal or dorsolateral). In VHL, multifocal involvement throughout the neuraxis is common. Q. What are the key radiologic features of intracranial hemangioblastoma? On MRI, cystic hemangioblastomas classically present as a vividly enhancing mural nodule adjacent to a non-enhancing, fluid-filled cyst. Solid hemangioblastomas enhance intensely and homogeneously. A critical diagnostic feature on both MRI and CT is the presence of prominent serpiginous flow voids within and around the tumor, representing high-flow feeding arteries and draining veins. On CT, the cyst component appears hypodense or hyperdense depending on protein content, and bony changes or hydrocephalus may be noted in posterior fossa lesions. Q. What are the characteristic MRI findings of spinal hemangioblastoma? Spinal hemangioblastoma typically appears on MRI as a small, brightly and homogeneously enhancing intramedullary nodule located along the posterior or posterolateral pial surface of the cord. Prominent serpiginous flow voids from feeding and draining vessels are commonly visible. The lesion is frequently accompanied by an extensive syrinx cavity, producing a classic "cyst with mural nodule" appearance analogous to cerebellar hemangioblastomas. Q. How does syringomyelia relate to spinal hemangioblastoma, and why is it diagnostically helpful? Syringomyelia is extremely common in spinal hemangioblastoma because even a tiny tumor alters local spinal fluid dynamics, causing fluid accumulation and cord expansion that is often disproportionately large relative to the small size of the enhancing nodule. This provides a crucial diagnostic clue: finding a massive syrinx driven by a tiny, brightly enhancing pial nodule strongly points toward hemangioblastoma over infiltrative intramedullary gliomas. Clinically, the syrinx also explains neurological deficits extending far beyond the focal anatomical level of the nodule itself. Q. How can spinal hemangioblastoma be differentiated from ependymoma and astrocytoma on imaging? Hemangioblastoma: Shows a small, eccentric (posterolateral) brightly enhancing pial nodule, prominent flow voids, and a disproportionately large syrinx relative to the nodule size. Ependymoma: Typically centrally located within the spinal cord, causing symmetric cord expansion with uniform, intense contrast enhancement and frequent "polar caps" of hemosiderin capping the tumor margins. Astrocytoma: Infiltrative, eccentrically placed, with ill-defined or patchy contrast enhancement, indistinct tumor margins, and less prominent syrinx formation relative to overall cord infiltration. Q. What are the main differential diagnoses for posterior fossa hemangioblastoma? Key differential diagnoses include pilocytic astrocytoma, hypervascular metastasis (e.g., renal cell carcinoma metastasis), arteriovenous malformation (AVM), and cystic meningioma. Hemangioblastoma is favored when imaging shows a combination of a brightly enhancing mural nodule, prominent flow voids, early venous drainage, and location in an adult posterior fossa (especially if VHL risk factors or polycythemia are present). Q. What are the differential diagnoses for supratentorial hemangioblastoma? For cystic supratentorial hemangioblastomas, key considerations include pilocytic astrocytoma and cystic metastasis. For solid, brightly enhancing supratentorial lesions, the differential includes hypervascular metastasis, arteriovenous malformations, and dural-based meningiomas. The presence of marked vascular flow voids and early venous drainage helps distinguish hemangioblastoma from extra-axial or infiltrative lesions. Q. What is the role of MR angiography (MRA) and digital subtraction angiography (DSA) in hemangioblastoma? MRA and DSA characterize the lesion's angioarchitecture by demonstrating a dense, intense tumor blush supplied by distinct feeding arteries and accompanied by early draining veins (reflecting rapid arteriovenous transit). In spinal lesions, selective angiography maps feeders relative to the anterior spinal artery and radiculomedullary supply (such as the artery of Adamkiewicz). In intracranial lesions, angiography confirms the compact AVM-like behavior, guiding the intraoperative devascularization sequence and helping determine if preoperative embolization is safe. Q. What are the fundamental surgical principles, vascular rules, and roles of embolization in managing hemangioblastoma? AVM-like Surgical Philosophy: The cardinal rule is stepwise circumferential arterial devascularization before venous sacrifice. Feeding arteries are coagulated and divided first. The main draining vein must be preserved until the nodule is fully devascularized, pale, and mobile. Premature venous occlusion causes immediate venous congestion, swelling, and catastrophic tearing hemorrhage. Piecemeal Debulking Avoidance: Internal debulking must never be performed before devascularization, as it creates uncontrolled bleeding from fragile intrinsic vascular channels. Cyst Wall Management: In cystic lesions, the cyst wall is reactive; complete resection of the enhancing nodule is fully curative, and cyst wall excision is unnecessary. Role of Preoperative Embolization: Selective and non-routine. Reserved for large, solid tumors with well-defined feeders inaccessible via early operative corridors. Avoided when feeders arise from critical perforators or the anterior spinal circulation. Q. How will you work up, perform surgery on, and postoperatively manage a patient with a posterior fossa hemangioblastoma? Preoperative Workup: Neuraxis MRI (brain/spine) to evaluate multiplicity, MRA/DSA for vascular mapping, and systemic VHL screening if indicated. Operative Positioning & Exposure: Prone or park-bench position. Suboccipital craniectomy (unilateral or bilateral midline based on laterality) with cisterna magna CSF release for brain relaxation. Microsurgical Technique: Identify the cyst and mural nodule. Map feeders and the primary draining vein. Coagulate and divide arterial feeders (PICA/SCA branches) circumferentially. Once the nodule becomes pale and flaccid, divide the draining vein, remove the nodule en bloc, and aspirate cyst fluid. Risk Mitigation & Postoperative Care: Prevent excessive bleeding through strict arterial-first control; preserve arachnoid planes to prevent cranial nerve/brainstem injury. Monitor postoperatively for edema, hydrocephalus, and sodium shifts. Obtain an early MRI (within 48 hours) to verify total nodule excision. Q. How will you plan, perform, and safely execute surgery for a spinal hemangioblastoma while preserving spinal cord function? Preoperative Planning & Approach: High-resolution MRI, DSA when needed, and neuromonitoring (MEPs/SSEPs). Perform a posterior midline exposure with laminectomy or laminoplasty (one level above and below). Use intraoperative ultrasound and ICG videoangiography. Vessel Identification & Testing: Feeders: Smaller, bright red, pulsatile, entering base/pial surface (early filling on ICG). Drainers: Larger, thin-walled, dark/purplish, non-pulsatile outflow (delayed filling on ICG). Micro-Doppler & Temporary Clips: Confirm flow velocity; temporary feeder clipping blanches the tumor, whereas draining vein clipping causes instant engorgement. Protection of the Artery of Adamkiewicz: Localized preoperatively via selective spinal angiography (typically T8–L2 on the left with a hairpin turn). Intraoperatively confirmed via ICG/Doppler; never sacrificed. Neuromonitoring Stopping Rules: Any >50% drop in MEP amplitude temporally linked to vessel manipulation demands immediate reversal, vessel un-clipping, warm irrigation, and hemodynamic optimization. Resection Steps (Dorsal/Dorsolateral): Open dura and identify pial corridor. Dissect along circumferential capsule planes, eliminating arterial feeders while preserving the main draining vein and anterior spinal axis. Coagulate and divide the draining vein last, then remove the nodule en bloc. Q. How do you approach supratentorial and brainstem hemangioblastomas, and what are the intraoperative stopping rules? Supratentorial Hemangioblastoma: Position for optimal venous drainage and perform a tailored craniotomy. Dissect pial-based or deep corridors to gain circumferential arterial control first. Preserve draining veins until complete devascularization occurs, then remove en bloc without resecting non-enhancing cyst walls. Brainstem Hemangioblastoma: Strict selection favoring pial/exophytic lesions over deep intraparenchymal tumors. Approach via cisternal/arachnoid corridors using high magnification and continuous neuromonitoring. Operative Stopping Rules for Brainstem Lesions: Cease resection and accept subtotal removal if circumferential devascularization requires sacrificing critical brainstem perforators, if uncontrolled bleeding occurs from deep inflow, if sustained neuromonitoring loss occurs, or if natural dissection planes are lost. Q. How do you step-wise differentiate feeding arteries from draining veins (feeders vs. drainers) intraoperatively during neurosurgical resection of a hemangioblastoma or AVM? A. Intraoperative distinction between feeding arteries and draining veins follows a strict, step-wise multimodal protocol: Microscopic Visual Inspection: Feeders: Thicker, opaque, arterialized walls; brighter red oxygenated blood; smaller diameter; entering deep or along pial borders toward the tumor capsule. Drainers: Thin, translucent, dark or arterialized ("red vein") walls; larger diameter; emerging directly out of the tumor bed and coursing toward distant venous sinuses. Manual & Tactile Assessment: Feeders: Highly pulsatile with high-resistance tension; firm under micro-bipolar forceps tips. Drainers: Turgid but non-pulsatile or low-amplitude venous pulsation; easily compressible with micro-instruments; turgor directly depends on tumor perfusion. Micro-Doppler Sonography: Feeders: High-velocity, sharp, high-pitch systolic sound profile with high resistance (rapid acoustic pulse). Drainers: Continuous, low-pitch, wave-like, low-velocity continuous flow sound without a sharp systolic spike. Indocyanine Green (ICG) Videoangiography: Arterial Phase (Early): Feeding arteries light up instantaneously in the early arterial phase, before the tumor nodule illuminates. Nodule Phase: The tumor parenchyma fills intensely. Venous Phase (Late): Draining veins light up last, filling as outflow channels leaving the capillary/tumor bed. Temporary Occlusion (Tamponade / Clip Test): Temporary Feeding Artery Occlusion: Application of a micro-clip or gentle temporary micro-forceps compression leads to immediate blanching and softening/turgor loss of the tumor nodule and reduced turgor in downstream drainers. Temporary Draining Vein Occlusion (CRITICAL RISK): Occlusion causes rapid, acute engorgement, swelling, dark discoloration, and micro-tearing of the tumor nodule. Release clip immediately. Q. What is the long-term management strategy, surveillance protocol, and overall philosophy for VHL-associated hemangioblastomas? Core Philosophy: Priority is placed on long-term functional preservation rather than radiographic total clearance of all lesions over a patient's lifetime. Selective Surgical Intervention: Surgical treatment is reserved strictly for symptomatic lesions, progressive neurological deficits, or expanding cysts/syringes. Asymptomatic, quiescent lesions are observed to avoid cumulative surgical morbidity. Surveillance Protocol: CNS Imaging: Serial brain and spine MRIs every 1–2 years. Systemic Screening: Annual ophthalmologic examination (retinal angiomas), periodic biochemical screening (plasma/urinary metanephrines for pheochromocytoma), and abdominal imaging (US/CT/MRI for RCC and pancreatic tumors). Genetics: Formal genetic counseling and family cascade testing for VHL gene mutations. Q. What is the role of systemic therapeutics (Belzutifan) in von Hippel–Lindau (VHL) disease-associated hemangioblastomas? A. Systemic medical therapy centered on small-molecule HIF-2 alpha inhibition has revolutionized VHL management: Primary Agent: Belzutifan (MK-6482), a potent, selective oral hypoxia-inducible factor-2 alpha (HIF-2 alpha) inhibitor. Clinical Indications: Approved for adult patients with VHL disease who require treatment for associated CNS hemangioblastomas, renal cell carcinomas (RCC), or pancreatic neuroendocrine tumors (pNETs) not requiring immediate surgical intervention. Efficacy & Impact: Demonstrates significant, durable objective response rates with tumor volume reduction. It alters the treatment paradigm by delaying or obviating the need for repeated, high-risk neurosurgical resections. Adverse Effects: Anemia (due to EPO suppression; requires baseline and periodic hemoglobin monitoring), hypoxia, fatigue, headache, and dizziness.

Arachnoid Cyst Q. What is an arachnoid cyst? An arachnoid cyst is a congenital, CSF-filled lesion arising from splitting or duplication of the arachnoid membrane. It is lined by arachnoid cells, contains fluid nearly identical to CSF, and displaces adjacent brain parenchyma, sometimes remodeling bone. It is not a neoplasm and is distinct from post-traumatic leptomeningeal cysts. Although arachnoid cysts may occur anywhere along the neuraxis, the most common sites are the middle cranial fossa, cerebellopontine angle, suprasellar region, and posterior fossa. Arachnoid cysts also occur in the spine. Q. What is the epidemiology of intracranial arachnoid cysts? Autopsy series report an incidence of approximately 1 per 500 persons. Arachnoid cysts comprise around 1% of all intracranial masses. They occur more commonly in males, with a male-to-female ratio of 4:1, and are more frequently found on the left side. Bilateral arachnoid cysts can occur, particularly in patients with metabolic disorders such as mucopolysaccharidoses. Q. What are the microscopic and histologic characteristics of arachnoid cysts? Two histological patterns exist: “Simple” arachnoid cysts show a delicate arachnoid lining with cells capable of minimal CSF secretion. Middle fossa cysts are almost always of this type. Complex cysts contain a mixed lining with potential mucin, ependyma, or other cell types, especially in unusual locations or syndromic patients. Arachnoid cysts are lined by epithelial membrane antigen–positive arachnoid cells and are negative for tumor markers such as CEA. Q. How are middle cranial fossa arachnoid cysts classified (Galassi)? The Galassi classification applies to Sylvian fissure/middle fossa cysts and contains three types: Type I: Small, anterior, biconvex cysts at the temporal tip, minimal mass effect, communicate freely with the subarachnoid space. Type II: Intermediate-sized cysts involving the proximal and intermediate Sylvian fissure; the insula is partly exposed; partial communication with the subarachnoid space is common. Type III: Large cysts occupying the entire middle cranial fossa, producing marked midline shift and bony expansion (elevation of sphenoid wing, outward displacement of squamous temporal bone). These have minimal communication with the subarachnoid space. Q. How are arachnoid cysts classified by location? Almost all arachnoid cysts occur in relation to an arachnoid cistern (intracisternal). The only exception is intrasellar cysts, which are extradural. Based on location, common sites include: • Sylvian fissure (most common, approximately half of all cysts) • CPA region • Supracollicular (quadrigeminal plate) • Vermian/posterior fossa • Sellar/suprasellar region • Interhemispheric fissure • Cerebral convexity • Clival • Spinal arachnoid space Q. How do arachnoid cysts form? They arise during embryogenesis from splitting or non-fusion of arachnoid membranes, creating a pocket that fills with CSF. They are therefore considered intra-arachnoid compartments. Fluid accumulates via CSF pulsation, passive diffusion, or a ball-valve effect. Secondary cysts may arise after infection, hemorrhage, trauma, or surgery; these have thickened walls or multiple septations. Q. What mechanisms allow arachnoid cysts to enlarge? Several mechanisms exist: A one-way valve leading to progressive CSF inflow Entrapment of CSF within an isolated arachnoid compartment Compression of adjacent arachnoid cisterns leading to unidirectional filling Intrinsic secretion from the cyst wall (rare) Impaired reabsorption or scarring of subarachnoid pathways Q. What is the importance of location in clinical presentation? Location determines which structures are compressed: Sylvian fissure: temporal lobe compression can lead to seizures and headaches Posterior fossa/vermis: hydrocephalus, ataxia Suprasellar: visual deficits, endocrine symptoms, precocious puberty, bobble-head doll syndrome, hydrocephalus Quadrigeminal plate: compression of posterior third ventricle can lead to obstructive hydrocephalus Convexity/interhemispheric: focal deficits, seizures Spinal: myelopathy, radicular pain Q. How do arachnoid cysts present clinically? Most are asymptomatic. Symptoms, when present, depend on location and cyst size. Typical presentations include: Intracranial hypertension: headache, nausea, vomiting, lethargy, irritability (especially in infants with large cysts). Seizures: particularly with middle fossa cysts due to temporal lobe irritation. Sudden deterioration: from intracystic or subdural hemorrhage (especially middle fossa cysts with tearing of bridging veins). Focal neurological deficit: due to space-occupying effect. Cosmetic skull deformity: outward bulging over the cyst. Incidental discovery: on imaging for unrelated issues. Suprasellar cysts have additional typical features: Hydrocephalus due to third ventricle/aqueduct compression Visual loss Endocrine disturbances including precocious puberty (occurs in up to 60%) “Bobble-head doll syndrome” (rare but classic), characterized by repetitive anteroposterior head movements Q. What CT features suggest an arachnoid cyst? CT shows a smooth, well-demarcated, non-calcified lesion with density nearly identical to CSF and no enhancement. Chronic cysts remodel adjacent bone in up to two-thirds of supratentorial and up to 80% of infratentorial cysts. The cyst may cause mass effect on adjacent structures, including lateral ventricle distortion or midline shift. Q. What MRI findings are characteristic of an arachnoid cyst? MRI is superior for evaluating cysts. The cyst follows CSF on all sequences: • Low T1, high T2 signal • Suppression on FLAIR • No diffusion restriction (epidermoids restrict) • No enhancement • Fine membranes may be visible on CISS/FIESTA sequences MRI can also show mass effect on the third/fourth ventricles, obstruction of foramina of Monro or aqueduct, and presence of septations. Q. What is the role of CT cisternography? CT cisternography involves the injection of intrathecal water-soluble contrast followed by high-resolution CT to evaluate contrast entry into the cyst. It is useful for: Determining communication between the cyst and subarachnoid space Differentiating true arachnoid cysts from loculated CSF spaces or diverticula Preoperative planning for fenestration (identifying best drainage pathways) Evaluation of intraventricular or posterior fossa cysts when MRI is inconclusive Confirming patency of a fenestration postoperatively Because some cysts only partially fill with contrast, interpretation must be correlated with MRI. Q. What are the treatment options for arachnoid cysts? Treatment depends on cyst location, size, symptoms, and communication with adjoining cisterns. Options include: Endoscopic fenestration into basal cisterns, ventricles, or both. Microsurgical fenestration via a craniotomy when endoscopic access is difficult or the cyst is multiloculated. Cystoperitoneal shunt as a definitive, low-recurrence option when other methods fail or are anatomically unsafe. Suboccipital or retrosigmoid fenestration for posterior fossa cysts. Spinal cyst fenestration or excision for intradural spinal lesions. Drainage alone (needle aspiration or burr hole) is avoided due to high recurrence. Ventricular drainage is contraindicated because it can worsen cyst enlargement. Q. What is the treatment of middle fossa arachnoid cysts? Middle fossa (Sylvian fissure) cysts are best treated by microsurgical fenestration into the basal cisterns, especially for large Type III lesions. Small, asymptomatic Type I lesions often require no treatment. Type II cysts may be treated with endoscopic fenestration when safe trajectories exist; however, microsurgical fenestration provides the most reliable and durable communication with the bulk cisterns. If fenestration fails or anatomy is unfavorable, cystoperitoneal shunting offers excellent long-term control and low recurrence. Q. What is the best treatment for suprasellar arachnoid cysts? The best and most durable treatment for suprasellar arachnoid cysts is endoscopic ventriculocystocisternostomy (VCC). This creates a wide communication between: The cyst The third ventricle The interpeduncular and prepontine cisterns VCC allows continuous CSF circulation and has the lowest recurrence rate among all treatments. Endoscopic ventriculocystostomy (VC) alone is less durable because it does not reestablish cisternal flow. Microsurgical subfrontal approaches are reserved for cases where endoscopic access is not possible. Q. What is the best treatment for posterior fossa arachnoid cysts? Posterior fossa cysts compressing brainstem or cerebellum are treated via a midline suboccipital or retrosigmoid fenestration into the cisterna magna or prepontine cistern. Endoscopic treatment is rarely feasible in posterior fossa due to limited endoscopic corridors. Q. What is the best treatment for intraventricular arachnoid cysts? These lesions are treated by neuroendoscopic fenestration into the ventricular system and adjacent cisterns. CT cisternography can help determine communication before surgery. Shunting is reserved for multiloculated or recurrent cysts. Q. How will you surgically treat an arachnoid cyst? (Microsurgical Fenestration) I will begin by reviewing high-resolution MRI, focusing on the cyst’s relationship to arteries, veins, cranial nerves, ventricles, and cisterns. Based on its location, I will select an optimal operative approach. For middle fossa cysts, I will commonly use a pterional craniotomy. For suprasellar cysts, I will plan a burr hole approach for neuroendoscopic ventriculocystocisternostomy. For posterior fossa lesions, I will choose a midline suboccipital or retrosigmoid exposure. After positioning and preparing the patient, I will open the dura and gently expose the cyst wall under the microscope or endoscope. I will cautiously dissect arachnoid membranes away from the cyst, protecting cortical vessels and perforators. Once I identify the cisternal or ventricular boundary, I will create a wide fenestration in the cyst wall using microscissors or bipolar forceps, ensuring a robust opening that cannot close spontaneously. If the cyst has internal septations, I will open each one to create a single cavity. For suprasellar cysts, I will identify the floor of the third ventricle, the lamina terminalis, and the interpeduncular cistern, and I will perform a ventriculocystocisternostomy to establish strong dual communication with both ventricle and cistern. I will confirm that CSF flow passes freely through the fenestrations and that no neural or vascular structures are entrapped. If the fenestration is not feasible or if the cyst is multiloculated and deep, I will place a cystoperitoneal shunt using a low-pressure valve to maintain gradual decompression. I will then irrigate, achieve hemostasis, and close all layers meticulously. Postoperatively, I will monitor for neurological improvement, signs of CSF leak, and subdural collections. Follow-up MRI will confirm cyst decompression and patency of fenestrations. Q. What are the perioperative complications of arachnoid cyst surgery? These include: Injury to adjacent cortex, cranial nerves, or perforator vessels Hemorrhage into the cyst or subdural space CSF leak Failure to adequately fenestrate cyst walls Injury to optic apparatus in suprasellar cases Brainstem injury in posterior fossa approaches Q. What are the postoperative complications? Postoperative complications include: Subdural hygroma (most common) due to rapid decompression of a large cyst Subdural hematoma Recurrence due to closure of fenestration Persistent hydrocephalus Shunt dependency if a shunt was placed Seizures in patients with temporal lobe involvement Visual or endocrine deterioration in suprasellar cysts if decompression is inadequate Q. How will you counsel the patient or parents before surgery? I will explain that arachnoid cysts are benign lesions that often remain stable, but surgery is indicated when symptoms or progressive enlargement occur. I will emphasize that the goal is to restore normal CSF circulation by fenestrating the cyst into cisterns or ventricles. I will discuss risks such as subdural collections, recurrence, cranial nerve deficits (depending on location), and the possibility of needing a shunt. For suprasellar cysts, I will clarify that endoscopic ventriculocystocisternostomy offers the best long-term results and carries a low recurrence rate. I will address seizure prognosis in temporal cyst cases and reassure parents that many children improve after decompression. Q. What is the prognosis after surgery for arachnoid cysts? Prognosis is excellent. Most symptomatic patients show significant improvement in headaches, hydrocephalus, visual symptoms, or developmental delay. Suprasellar cyst symptoms, especially visual decline and bobble-head doll syndrome, often improve dramatically with timely VCC. Recurrence is uncommon when wide fenestrations are created. Shunted cysts function well but require lifelong surveillance for shunt malfunction. Seizure control depends on underlying cortical pathology; some patients continue to require antiepileptic therapy despite cyst decompression. Reference: Greenberg's Handbook of Neurosurgery, 10th Edition

Sylvian Fissure Anatomy & Splitting Sylvian Fissure Anatomy Part 1 A detailed overview of the microsurgical anatomy and initial orientation required for a successful Sylvian fissure split. Understanding the surface landmarks and vascular relationships is critical before beginning the dissection. Sylvian Fissure Anatomy Part 2 Build on your understanding of the Sylvian Fissure in this focused Part 2 session, designed to simplify microsurgical anatomy and dissection concepts. Sylvian Fissure Splitting Master Sylvian fissure splitting with a clear, step-by-step approach designed for neurosurgery residents and trainees. This video breaks down microsurgical anatomy, safe dissection planes, arachnoid opening techniques, and key operative landmarks essential for pterional and transsylvian approaches.

Cranial Modules Adult Diffuse Gliomas Pediatric Diffuse Gliomas Hemangioblastoma Medulloblastomas Pilocytic Astrocytoma Meningiomas Ependymomas Brainstem Module Approaches to Ventricles Cranial Neurosurgical Approaches Pituitary Adenoma & EETS Sylvian Fissure Anatomy & Splitting

The Team A global community of neurosurgeons, educators, and collaborators working together to advance neurosurgical education. About the Founder Background, journey and vision behind TNCR. The Team Meet the core team behind TNCR. TNCR Representatives Our representatives supporting TNCR’s global community.

Infections Cerebral Abscess → Intracranial Fungal Granuloma → Subdural Empyema →

Klippel Feil Syndrome Klippel–Feil Syndrome (KFS) is a congenital disorder characterized by fusion of two or more cervical vertebrae, involving either the vertebral bodies alone (congenital block vertebrae) or the entire vertebra including the neural arches. Q. What is the embryologic basis of Klippel–Feil Syndrome? KFS results from failure of segmentation of cervical somites during the 3rd–8th week of embryogenesis, leading to congenital fusion. This segmentation failure is analogous to other craniovertebral segmentation anomalies such as occipitalization of the atlas and basilar invagination. Q. What is the classic clinical triad of KFS? Present in <50% of patients: Short neck (brevicollis), Low posterior hairline, Restricted cervical motion, most marked in rotation. Most patients with congenital cervical fusion have normal external appearance, and the triad is often absent. Symptoms result from hypermobility and degeneration in non-fused adjacent segments. Q. What are the associated abnormalities in KFS? Visceral anomalies: • Renal dysfunction: ↑ albumin, ↑ BUN, ↑ creatinine • Respiratory: wheezing • Cardiovascular: arrhythmias, complete heart block Skeletal / neurological associations: • Scoliosis • Spina bifida • Atlantoaxial dislocation • Hemivertebrae • Occipitalization of atlas • Cervical canal stenosis (uncommon) Chiari I association: • KFS occurs in roughly 3% of Chiari I malformation patients. Q. What is the classification of Klippel–Feil Syndrome? 1. Clarke–Feil Classification: Type I: Massive fusion of many cervical and upper thoracic vertebrae. Type II: Fusion of one or two cervical vertebrae + other cervical anomalies (hemivertebrae, atlanto-occipital fusion). Type III: Cervical fusion + lower thoracic or lumbar fusion. Importance: • Useful for describing extent of fusion • Limited value for surgical planning due to wide anatomic variability 2. Samartzis Classification: This is the current standard in spine surgery. Type I: Single congenitally fused cervical segment. Type II: Multiple non-contiguous fused segments. Type III: Multiple contiguous fused segments. Clinical relevance: • Type II and III carry highest risk for degenerative adjacent-segment disease, • Type I may remain asymptomatic. This classification correlates strongly with pain, myelopathy, and adjacent level degeneration, making it far more practical for surgical decision-making. 3. Functional Classification (Boddu et al.) Based on mobility and neurologic risk rather than number of fused levels. Stable KFS: • No instability or cord compression • Managed conservatively Unstable KFS: • Demonstrable atlantoaxial or subaxial instability • Requires surgical stabilization Q. What are the radiologic features of KFS? • Fused vertebrae (most commonly C2–C5) • Hypoplastic or absent disc spaces • Flattened and malformed vertebral bodies • Hemivertebrae • Narrow oval neural foramina • Cervical scoliosis • Spina bifida • Atlantoaxial instability MRI is required when evaluating cord compression or associated craniovertebral anomalies. Q. What investigations are recommended? Laboratory: • Urine: ↑ albumin, ↓ urine volume • Blood: ↑ BUN, ↑ creatinine Imaging: • X-ray / CT for bony anatomy • MRI for spinal canal, cord, Chiari malformations, syrinx • Dynamic flexion–extension X-rays for instability • Renal ultrasound for congenital kidney anomalies Q. What are important clinical implications of KFS? • Hypermobility of adjacent segments leads to early degenerative changes • Risk of atlantoaxial instability • C-spine anatomy makes airway management difficult • Higher risk of spinal cord injury even with minor trauma, especially in Type II and III • Associated with Chiari I and craniovertebral junction anomalies • Progressive scoliosis in childhood Q. How will you manage a patient with Klippel–Feil Syndrome? Conservative Management First line for most cases: • Analgesics • Muscle relaxants • Physiotherapy Avoid contact sports due to risk of SCI. Surgical Indications • Craniovertebral instability • Spinal cord compression • Cervical radiculopathy/myelopathy • Atlantoaxial dislocation • Progressive scoliosis • Severe adjacent segment degeneration • Basilar invagination • Persistent pain unresponsive to therapy • Vertebral artery anomalies requiring decompression Surgical Options • Occipitocervical fusion for craniovertebral instability • C1–C2 fusion for atlantoaxial instability • Subaxial decompression and fusion for stenosis and myelopathy • Scoliosis correction if structural and progressive Q. What complications can occur in KFS? • Degenerative cervical spine disease • Instability at adjacent mobile segments • Myelopathy • Vertebral artery anomalies (important during surgery) • Respiratory problems • Congenital cardiac and renal issues • Neurologic deterioration after minor trauma Q. What is the prognosis? Depends on: • Number of fused levels (Samartzis Type I vs II/III) • Presence of instability • Cord compression • Associated craniovertebral anomalies • Associated organ anomalies Patients with single-level fusion (Samartzis Type I) often remain asymptomatic. Multiple-level fusions carry higher risks of pain, degeneration, instability, and neurologic deficits. Q. Why are the renal anomalies associated with KFS? Renal abnormalities in Klippel–Feil Syndrome occur because the same embryologic processes that form the cervical vertebrae also contribute to the development of the kidneys. Both structures originate from adjacent mesodermal segments during the third to eighth weeks of gestation. When there is a segmentation failure leading to fused cervical vertebrae, the nearby intermediate mesoderm responsible for renal formation may also develop abnormally. As a result, congenital renal anomalies such as dysplasia, agenesis, malrotation, or collecting-system defects may occur.

SPINE Cervical Laminectomy Cervical Laminoplasty Cervical Stenosis and CSM Cervical Disc Disease Cervical Lateral Mass Screw Fixation Failed Back Surgery Syndrome Lumbar Canal Stenosis Lumbar Disc Disease Occipitocervical Fusion OPLL Posterior Cervical Foraminotomy Spine Long Cases/TOACS Spinal Screw Summary Thoracic Costotransversectomy Approach Transoral Odontoidectomy Treatment of Subaxial Cervical Spine Injuries

Approaches to Ventricles Endoscopic Third Ventriculostomy | Part 1 Rather than jumping directly into the operation, Part 1 develops the conceptual orientation every neurosurgeon, resident, and medical student needs before performing or understanding ETV. By the end of this session, you will be able to identify the critical structures that define the surgical corridor and appreciate the anatomical relationships that determine a safe ventriculostomy. Endoscopic Third Ventriculostomy | Part 2 In Part 2 of our Endoscopic Third Ventriculostomy (ETV) series, we take a rapid, high-yield review of the procedure with a practical surgical focus. Learn the indications, contraindications, patient selection, ETV Success Score (ETVSS), essential ventricular anatomy, operative steps, technical pearls, complications, and postoperative considerations. Designed for neurosurgery residents, medical students, and practicing neurosurgeons preparing for exams or operative cases. Approaches to the Lateral Ventricle | Transcortical vs Transcallosal vs Endoscopic Corridors This video reviews the principles behind choosing the optimal operative corridor, including the transcortical, transcallosal, and neuroendoscopic approaches, with emphasis on indications, anatomical landmarks, advantages, limitations, and surgical decision-making. Anterior Interhemispheric Transcallosal Approach | Anatomy, Indications & Surgical Technique This comprehensive neurosurgical lecture reviews the microsurgical anatomy of the interhemispheric fissure, corpus callosum, lateral ventricles, septum pellucidum, fornix, and deep venous system. Learn patient positioning, craniotomy planning, surgical corridor selection, ventricular entry, indications, advantages, limitations, complications, and operative pearls for safely approaching intraventricular lesions. Ideal for neurosurgery residents, fellows, practicing neurosurgeons, and medical students preparing for examinations and operative practice. Transchoroidal & Subchoroidal Approaches Master the Transchoroidal and Subchoroidal approaches to the third ventricle in this comprehensive neurosurgical anatomy lecture from The Neurosurgical Case Room (TNCR). This module explains the microsurgical anatomy of the choroidal fissure, velum interpositum, internal cerebral veins, fornix, tela choroidea, and the key surgical corridors used to safely access third ventricular lesions. Ideal for neurosurgery residents, fellows, and practicing neurosurgeons preparing for exams or refining operative planning.

Occult Spinal Dysraphisms & Filar Pathologies This Section includes: Meningocele Dermal Sinus Filar Lipoma Tight Filum Terminal Myelocystocele MENINGOCELE: Q. What is a meningocele? A meningocele is a closed spinal dysraphism consisting of a CSF-filled sac that herniates through a posterior bony defect, but contains no neural tissue. The spinal cord remains within the canal, and the sac is covered by skin. It results from failure of dorsal vertebral arch formation with intact neural tube closure. Q. How does a child with meningocele present clinically? Most present with a midline, skin-covered swelling in the lumbosacral region. Neurological examination is typically normal because neural elements do not herniate into the sac. However, some children may have associated anomalies such as tethered cord, split cord malformation, or dermal sinus, so subtle motor, bladder, or foot abnormalities may coexist. Q. How is a meningocele managed? MRI is performed to confirm absence of neural tissue in the sac and to evaluate associated dysraphism. Surgical treatment involves simple excision of the meningocele sac and watertight dural closure. Because the cord is not included, neurological risk is low. Associated anomalies (e.g., tethered cord, dermal sinus, SCM) must be identified and addressed accordingly. DERMAL SINUS TRACT: Q. What is a dermal sinus tract? A dermal sinus tract is a congenital epithelial-lined channel extending from the skin surface toward the underlying neural elements due to failure of complete dysjunction between surface ectoderm and neural ectoderm during primary neurulation. It may terminate in subcutaneous tissue, dura, thecal sac, or even attach to the spinal cord, and frequently coexist with dermoid or epidermoid inclusion tumors. Q. How does a dermal sinus tract present clinically? Clinically, it appears as a midline skin dimple or pit, often with hair, discharge, or recurrent local infection. Neurological findings may result from tethered cord or inclusion tumors. Recurrent meningitis or abscess is a classic presentation because the tract provides a direct path for infection from the skin to the thecal sac. Q. How is a dermal sinus tract managed? Management is complete surgical excision of the tract using microsurgical techniques with intradural exploration to remove any associated dermoid/epidermoid tumor and to detether the cord. Early surgery is recommended even if asymptomatic because of the high risk of meningitis and progressive neurological decline. FILAR LIPOMA: Q. What is a filar lipoma? A filar lipoma is a fatty infiltration of the filum terminale, caused by abnormal differentiation of caudal mesenchyme during secondary neurulation. It may tether the conus and restrict its ascent, often associated with a low-lying conus. Q. How does a filar lipoma present clinically? Most are asymptomatic early in life but may later present with tethered cord symptoms such as back pain, gait issues, foot deformities, scoliosis, or bladder dysfunction. Many are discovered incidentally during MRI for other reasons. Q. How is a filar lipoma managed? Treatment is surgical sectioning of the filum terminale when symptomatic or when imaging demonstrates a low conus with evidence of tethering. Surgery is straightforward and carries low neurological risk because the filum contains no functional neural elements. TIGHT FILUM TERMINALE: Q. What is a tight filum terminale? A tight filum terminale is an abnormally thickened, inelastic filum that tethers the conus medullaris, typically defined as a filum >2 mm in diameter. It may or may not contain fat and results from disordered canalization during secondary neurulation. Q. How does a tight filum present clinically? Children may present with tethered cord symptoms (leg pain, gait disturbance, urinary symptoms, or foot deformities) despite a skin-covered back. MRI often shows a low-lying conus (below L2–L3) and a thickened filum without a large lipomatous mass. Q. How is a tight filum managed? Management is simple filum sectioning through a small laminotomy. Intraoperative stimulation is used to confirm the structure is non-functional. Sectioning releases the tethering and prevents progression of neurological and urological deficits. TERMINAL MYELOCYSTOCELE: Q. What is a terminal myelocystocele? A terminal myelocystocele is a closed, skin-covered spinal dysraphism resulting from a failure of secondary neurulation, in which the distal spinal cord balloons outward into a CSF-filled terminal cyst that extends dorsally through a posterior bony defect while maintaining continuity with a low-lying conus. It characteristically shows a “trumpet-like” flaring of the distal spinal cord on MRI. Q. How does a child with terminal myelocystocele present clinically? Children typically present at birth with a lumbosacral midline mass covered with normal or stretched skin. The conus is low and tethered, so progressive neurological or urological symptoms can appear with growth (leg weakness, gait disturbance, foot deformities, or neurogenic bladder). Associated anomalies are common, including anorectal malformations and urogenital anomalies. Q. How is a terminal myelocystocele managed surgically? MRI defines the anatomy. Surgery involves untethering of the cord, decompression of the terminal cyst, and reconstruction of the distal neural tube. The cyst is opened, the distended terminal cord is reduced and contoured, and a generous duraplasty is performed to prevent further tethering. The wound is closed in layered fashion. Early surgery is favored to avoid progression of neurological deficits.